Trade Names:Semprex-D- Capsules 8 mg acrivastine/60 mg pseudoephedrine
Acrivastine: Competitively blocks histamine at H 2 receptor sites; pseudoephedrine: causes vasoconstriction and subsequent shrinkage of nasal mucous membranes by alpha-adrenergic stimulation, promoting nasal drainage.
Relief of symptoms associated with seasonal allergic rhinitis.
Hypersensitivity to any ingredient of product; known sensitivity to other alkylamine antihistamines (eg, triprolidine); patients with severe hypertension or coronary artery disease; MAOI therapy or within 14 days of stopping MAOI therapy.
PO 1 capsule (8 mg acrivastine/60 mg pseudoephedrine) every 4 to 6 h (up to 4 times daily).
Store capsules at controlled room temperature (59° to 86°F). Protect from light and moisture.
Additional decrease in alertness and impairment of CNS performance may occur.
Pseudoephedrine Antihypertensive agents that interfere with sympathetic activity (eg, mecamylamine, methyldopa, reserpine, veratrum alkaloids)Antihypertensive effects of these agents may be reduced.
DigitalisIncreased ectopic pacemaker activity may occur.
MAOIsContraindicated in patients taking MAOIs and for 14 days after stopping use of an MAOI.
May diminish or prevent positive reactions to skin tests.
Palpitations, tachycardia, pressor activity, cardiac arrhythmias, cardiovascular collapse (pseudoephedrine).
Somnolence; headache; dizziness; nervousness; insomnia.
Pharyngitis; increased cough.
Nausea; dyspepsia.
Dysmenorrhea.
Asthenia; hypersensitivity (anaphylaxis, angioedema, bronchospasm, erythema multiforme).
Category B .
Undetermined.
PseudoephedrineExcreted in breast milk.
Safety and efficacy not established in children less than 12 yr of age.
More likely to cause dizziness, sedation, bladder-neck obstruction, and hypertension.
Use is not recommended.
Use with caution in patients with hypertension, diabetes mellitus, ischemic heart disease, increased intraocular pressure, hyperthyroidism, psoriatic hypertrophy, stenosing peptic ulcer, or pyloroduodenal obstruction.
Convulsions, CNS stimulation or depression, cardiovascular collapse with hypotension, fear, anxiety, tenseness, restlessness, tremor, weakness, pallor, respiratory difficulty, dysuria, insomnia, hallucinations, convulsions, arrhythmia.
Copyright © 2009 Wolters Kluwer Health.